Recent approvals of therapeutic antibodies that block cytotoxic T lymphocyte associated antigen 4 (CTLA4) and programmed cell death protein 1 (PD1) in melanoma, non-small-cell lung cancer and kidney cancer illustrate the importance of identifying additional immune checkpoints that could be targeted clinically. The gene discussed is CTLA4; the disease is kidney cancer.